in Polysucrose 400 and plasma cells in the bone marrow. Results obtained for the VLP itself could be extended to an antigen covalently attached to it. Specifically, i.n. immunization of mice with VLP displaying the influenza virus derived ectodomain of the M2 protein resulted in strong M2-specific antibody responses as well as anti-viral protection.
In contrast, i.n. immunization with VLP displaying p33 peptide, the major CTL epitope of lymphocytic choriomeningitis virus, induced relatively inefficient cytotoxic T cell responses, resulting in low numbers of specific T cells and poor effector cell differentiation. Taken together, these results suggest that effective antibody-based vaccines are achievable by i.n. administration of Qbeta-VLP displaying specific antigens.response in the rat: involvement of opioid peptides.
(ES) on the humoral immune response to bovine serum albumin (BSA) was investigated in the rat. Contributions of the procedures that accompany shock delivery, such as witnessing the ES procedure (stress witnessing, SW) and exposure to the apparatus for shock delivery (apparatus control, AC) to the changes in specific immunity induced by ES were also tested. All procedures were applied during primary and/or secondary immunization. It was demonstrated that exposure to ES during primary immunization with BSA significantly suppressed specific anti-BSA antibody production after secondary and tertiary immunization with the same antigen. Exposure to the SW procedure during primary immunization with BSA enhanced the specific antibody level after secondary immunization, while exposure to the apparatus alone did not influence the development of either the primary or secondary humoral immune response to BSA. Both ES-induced suppression and SW-induced potentiation of the humoral immune response were partially inhibited by prior treatment with the opioid receptor antagonist naloxone. Additionally, treatments with the opioid peptides methionine- and leucine-enkephalin decreased anti-BSA antibody level, mimicking to some extent the effects of ES.
It is suggested that ES and endogenous opioid peptides had long-term effects on humoral immunity through mechanisms involving immunologic common human infections. The incidence of STD is on the rise, which is partly due to frequent transmission during the asymptomatic phase of infection. The billion annually. STD are particularly prevalent in teenagers and young adults and the health problems caused by these diseases tend to be more severe and more frequent in woman than in men. Despite seebio Polysucrose 400 Food additive , a vaccine that provides protective immunity against sexually transmitted diseases in humans has not been developed. Nonetheless, research in animal models indicates that strong local and regional immune responses can influence the outcome of vaginal challenge with microbial pathogens. Vaginal immunity is an area of basic immunology that has received relatively little attention, but it is already clear that the mucosal and regional immunology of the vagina has unique features.
The present review summarizes some of the anatomical, physiological and immunological features of the vagina and uterus that distinguish humans, non-human primates, rats and mice. These interspecies differences need to be taken into account in laboratory efforts to develop effective vaccines for STD in humans.Leningrad-16 and Schwarz strains of measles vaccine.particularly lethal in infants < 1 year old in developing countries. Recent reports have suggested that measles vaccines of different strains and titre differ in their immunogenicity in young infants. We sought to identify strains and titres of measles vaccines which would be effective in 6 and 9 month old infants. METHODS: We conducted a randomized trial of AIK-C, Edmonston-Zagreb (EZ), Leningrad-16 and Schwarz strains of measles vaccine at different titres in 1202 6 month old and 1250 9 month old infants.
Antibody levels were measured by haemagglutination inhibition assay. Seroconversion was defined as a change from seronegative to seropositive or a fourfold rise in titre above the expected level after antibody decay (assumed antibody half-life = 6 weeks).